Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …

Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …

Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …

The RE-LY study compared dabigatran in the dose of 150 mg and 110 mg twice daily,
without laboratory monitoring, with the conventional treatment with warfarin dosed according …

Background: Dabigatran exilate has emerged as a highly effective tool in treating atrial
fibrillation, AF). Its relative convenience in terms of cost and overall utility with respect to …

Background Economic evaluation of dabigatran, a new anti-antithrombotic agent, is done
mostly in Western countries. It remains to be seen whether dabigatran will be cost effective …

This article provides an overview of the clinical profile of oral dabigatran etexilate
(Pradaxa®, Pradax™)[hereafter referred to as dabigatran] when used for the prevention of …

Background: Dabigatran is a kind of oral anticoagulant and there was little review only about
dabigatran and warfarin used in patients with atrial fibrillation. This meta-analysis only …

Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …

Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …